Effect of ferric carboxymaltose vs. placebo on (A) total cardiovascular hospitalizations and cardiovascular death, (B) total heart failure hospitalizations and cardiovascular death, (C) total cardiovascular hospitalizations, (D) total heart failure hospitalizations, and (E) time to cardiovascular death. ^aRate ratios and P-values are estimated using a negative binomial model on the number of events, including (fixed covariates) treatment, region, haemoglobin level at baseline, and (random covariate) study. ^bThe hazard ratio, associated 95% confidence interval, and adjusted Wald P-value are from a Cox model fitted with fixed effects of treatment, subgroup, treatment by subgroup, haemoglobin at baseline, region, and a random effect of study, assuming proportional hazards. CI, confidence interval; CV, cardiovascular; FCM, ferric carboxymaltose; HF, heart failure; PBO, placebo; RR, rate ratio.